Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050000 | 0.89 | GSK3B (0.54) | GSK3BKDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL12876004 | 0.89 | GSK3B (0.58) | GSK3BKDM4EGAAALDH1A1PTPN1 | |
| SCHEMBL1189829 | 0.89 | GSK3B (0.58) | GSK3BKDM4EGAAALDH1A1PTPN1 | |
| SCHEMBL9199476 | 0.88 | GSK3B (0.53) | GSK3BKDM4EGAAALDH1A1ABCG2 | |
| SCHEMBL23360861 | 0.87 | GSK3B (0.56) | GSK3BKDM4EGAAALDH1A1PTPN1 | |
| SCHEMBL9907157 | 0.87 | GSK3B (0.56) | GSK3BKDM4EGAAPTPN1KMT2A | |
| SCHEMBL9198694 | 0.87 | GSK3B (0.51) | GSK3BKDM4EGAAALDH1A1ABCG2 | |
| SCHEMBL1190303 | 0.84 | GSK3B (0.53) | GSK3BKDM4EGAAPTPN1CES2 | |
| SCHEMBL9907151 | 0.84 | GSK3B (0.53) | GSK3BKDM4EGAAALDH1A1PTPN1 | |
| SCHEMBL1189491 | 0.84 | GSK3B (0.53) | GSK3BKDM4EGAAALDH1A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112209841-B | Synthesis method of terbutaline and application of terbutaline in preparation of terbutaline sulfate | 扬州中宝药业股份有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-115181082-A | Synthetic method of natural molecule Moracin M | 江苏集萃分子工程研究院有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3259256-B1 | COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE | BEIJING ERAI THERAPEUTICS CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| CN-112209841-B | Synthesis method of terbutaline and application of terbutaline in preparation of terbutaline sulfate | 扬州中宝药业股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-112209841-B | Synthesis method of terbutaline and application of terbutaline in preparation of terbutaline sulfate | 扬州中宝药业股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-04-13 | — | — | US | disclosed |
| CN-106946896-B | Furans simultaneously [2,3-d] pyrimidine -4- amine derivative | 成都知普莱生物医药科技有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| US-6025531-A | REACTING A PROCHIRAL KETONE WITH A MIXTURE BORON-CONTAINING COMPOUNDS HAVING A BORANE REACTION PRODUCT FROM OPTICALLY ACTIVE BETA-AMINOALCOHOL AND A BORON HYDRIDE OR A METAL BOROHYDRIDE, AND AN OPTICALLY ACTIVE OXAZABOROLIDINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0713848-B1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY (JP) | 1999-09-08 | — | — | EP | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| US-5831132-A | REDUCING AGENT FROM BORANES AND AMINO ALCOHOLS | SUMIKA FINE CHEMICALS COMPANY, LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5801280-A | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0736509-A2 | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-10-09 | — | — | EP | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0713848-A1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | GSK3B 4403/4885KDM4E 4376/4885GAA 3830/4885 |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HTR3D, PTGDR2, PTGIR | GSK3B 4244/4885KDM4E 4358/4885GAA 4471/4885 |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | GSK3B 4403/4885KDM4E 4376/4885GAA 3830/4885 |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | TBXA2R, HRH2, CYP4F3 | GSK3B 4628/4885KDM4E 4431/4885GAA 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.